Oral Market Analysis
Cross-industry research covering Oral across 2 market reportsspanning Pharmaceuticals & Medical Devices — Ophthalmic Surgery, Pharmaceuticals.
Reports Covering Oral
Oculoplastic Surgery Market to Reach USD 8.4 Billion by 2033 at 7.2% CAGR
Currently small but the highest-optionality route contingent on linsitinib Phase 2b/3 readout (NCT05276063); an oral TED therapy would bypass infusion infrastructure entirely and would likely be distributed through retail and mail-order specialty pharmacy, creating new channel partnerships for the originator.
8%
Market Share
23.4%
Segment CAGR
Hospital Acquired Infection Control Market to Reach USD 41.6B by 2033 at 6.4% CAGR
Oral antibiotics and antifungals are increasingly favored for IV-to-oral step-down strategies that reduce inpatient days, generating both cost savings for CMS-reimbursed stays and a channel shift from hospital direct to specialty and retail pharmacy. The SR1375 oral capsule trial in community-acquired pneumonia (nct:NCT06577558) illustrates pipeline investment in oral anti-infectives with potential HAI-adjacent applications.
28%
Market Share
6.8%
Segment CAGR